Phillip Schwartz - Entera Bio CEO, Director
| ENTX Stock | USD 2.05 0.06 3.02% |
CEO
Dr. Phillip Schwartz Ph.D., is Chief Executive Officer, Director of the company. He has more than ten years of biotech and pharmaceutical industry experience. He has held multiple positions in medical affairs, business development and clinical trial development at Serono and Endo Pharmaceuticals. He has also consulted privately and as an associate of Health Advances, LLC, for more than 20 large biotech and pharmaceutical companies. His former position was as the Manager of Clinical Affairs at Endo Pharmaceuticals. He has also worked as consultant for a number of VC firms.Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Prof. Torsten Wiesel of the Rockefeller University, for more than two years. After completing his project, Dr. Schwartz studied immunology with Prof. Irun Cohen at the Weizmann Institute, receiving his MSc, in 1991. In 1997 Dr. Schwartz received his PhD in neurobiology development oncology from Harvard Medical School. In addition to his scientific training, Dr. Schwartz completed two years of clinical studies as part of his program at Harvard Medical School. After completing his PhD, Dr. Schwartz was a fellow in pediatric oncology at the Dana Farber Cancer Institute and an officer of Harvard University Medical School. Dr. Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. since 2010.
| Age | 54 |
| Tenure | 14 years |
| Address | Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002 |
| Phone | 972 2 532 7151 |
| Web | https://www.enterabio.com |
Entera Bio Management Efficiency
The company has return on total asset (ROA) of (0.4465) % which means that it has lost $0.4465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.803) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 188.5 K in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Marc Voigt | Immutep Ltd ADR | 51 | |
| Alexander MBA | NLS Pharmaceutics AG | 55 | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.45 |
Entera Bio Leadership Team
Elected by the shareholders, the Entera Bio's board of directors comprises two types of representatives: Entera Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entera. The board's role is to monitor Entera Bio's management team and ensure that shareholders' interests are well served. Entera Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entera Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hillel MBA, Chief Officer | ||
| Hillel Galitzer, COO | ||
| Miranda MBA, CEO Director | ||
| Dana CPA, Chief Officer | ||
| Miranda Toledano, Independent Director | ||
| Sean Ellis, Director | ||
| Dana YaacovGarbeli, Interim CFO | ||
| Gerald Ostrov, Independent Director | ||
| Chaim Davis, Director | ||
| David Ami, Director | ||
| Zeev Bronfeld, Director | ||
| Adam Gridley, CEO | ||
| II MD, Chief Officer | ||
| Yeonatan Malca, Director | ||
| Mira Rosenzweig, CFO | ||
| Roger Garceau, Director | ||
| Faith Charles, Independent Director | ||
| Phillip Schwartz, CEO, Director | ||
| Arthur Santora, Chief Medical Officer | ||
| Gerald Lieberman, Chairman of the Board | ||
| Miriam Blum, Chief Medical Officer |
Entera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Entera Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 59.98 M | ||||
| Shares Outstanding | 35.48 M | ||||
| Shares Owned By Insiders | 19.89 % | ||||
| Shares Owned By Institutions | 10.47 % | ||||
| Number Of Shares Shorted | 88.21 K | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 10.18 X | ||||
| Price To Sales | 107.25 X |
Pair Trading with Entera Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Entera Stock
| 0.67 | ELYM | Eliem Therapeutics | PairCorr |
Moving against Entera Stock
| 0.74 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
| 0.71 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.66 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.59 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.56 | PCVX | VaxcyteInc Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Entera Stock analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.31) | Quarterly Revenue Growth (0.92) | Return On Assets (0.45) | Return On Equity (0.80) |
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Entera Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.